At the Annual General Meeting of RaySearch Laboratories AB (publ) held on 30 June 2020, the following resolutions were adopted.
The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the board and the CEO from liability. It was resolved that the accumulated profit, amounting to SEK 206,198,000 be brought forward and balanced in the new accounts.
It was resolved to adopt the guidelines for remuneration to senior executives proposed by the board.
It was resolved that remuneration to board members who do not receive a salary from any Group company, shall amount to SEK 700,000 to the chairman of the board and SEK 250,000 to each of the other board members elected by the general meeting.
It was resolved that the auditor’s fees be paid in accordance with approved invoicing and to re-elect the auditing firm Ernst & Young as auditor.
The Annual General Meeting also approved the board’s proposal regarding amendments of the articles of association.
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch’s software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
More information about RaySearch is available at www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59